title: Gastric and pancreatic lesions in rats treated with a pan-CDK inhibitor.
authors.affiliation: Worldwide Safety Sciences, Pfizer Global Research and Development, San Diego, California, 92121, USA. fernando.ramiro-ibanez@pfizer.com
authors.forename: Fernando
authors.initials: F
authors.lastname: Ramiro-Ibáñez
authors.forename: Dusko
authors.initials: D
authors.lastname: Trajkovic
authors.forename: Bart
authors.initials: B
authors.lastname: Jessen
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors*; D004791:Enzyme Inhibitors / Q000633:toxicity*; D007150:Immunohistochemistry; D008297:Male; D009336:Necrosis; D010179:Pancreas / Q000473:pathology*; D010446:Peptide Fragments / Q000633:toxicity*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013270:Stomach / Q000473:pathology*; D059005:Topoisomerase II Inhibitors; D014841:von Willebrand Factor / Q000633:toxicity*
chemical_list: D004791:Enzyme Inhibitors; D010446:Peptide Fragments; D059005:Topoisomerase II Inhibitors; D014841:von Willebrand Factor; C081839:von Willebrand factor (445-733); D018844:Cyclin-Dependent Kinases